Epidemiology of Stroke

Stroke

Volumn , Issue , 2011, Pages 198-218

  Wolf, Philip A ^a,b   Kannel, William B ^a,b  

^a FRAMINGHAM HEART STUDY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882879657     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5478-8.10014-4     Document Type: Chapter

References (135)

1. MacMahon B. Epidemiologic methods 1960, Little, Boston. ed 1.
2. Lloyd-Jones D., Adams R.J., Brown T.M., et al. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation 2010, 121(7):e46-e215.
3. Rosamond W.D., Folsom A.R., Chambless L.E., et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 1999, 30(4):736-743.
4. Ayala C., Greenlund K.J., Croft J.B., et al. Racial/ethnic disparities in mortality by stroke subtype in the United States, 1995-1998. Am J Epidemiol 2001, 154(11):1057-1063.
5. Sacco R.L., Ellenberg J.H., Mohr J.P., et al. Infarcts of undetermined cause: The NINCDS Stroke Data Bank. Ann Neurol 1989, 25(4):382-390.
6. Reed D.M. The paradox of high risk of stroke in populations with low risk of coronary heart disease. Am J Epidemiol 1990, 131(4):579-588.
7. Kase C.S., Wolf P.A., Chodosh E.H., et al. Prevalence of silent stroke in patients presenting with initial stroke: The Framingham Study. Stroke 1989, 20(7):850-852.
8. Chodosh E.H., Foulkes M.A., Kase C.S., et al. Silent stroke in the NINCDS Stroke Data Bank. Neurology 1988, 38(11):1674-1679.
9. Manolio T.A., Kronmal R.A., Burke G.L., et al. Magnetic resonance abnormalities and cardiovascular disease in older adults. The Cardiovascular Health Study. Stroke 1994, 25(2):318-327.
10. Vermeer S.E., Prins N.D., den Heijer T., et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003, 348(13):1215-1222.
11. Giele J.L., Witkamp T.D., Mali W.P., et al. Silent brain infarcts in patients with manifest vascular disease. Stroke 2004, 35(3):742-746.
12. Sacco R.L., Foulkes M.A., Mohr J.P., et al. Determinants of early recurrence of cerebral infarction. The Stroke Data Bank. Stroke 1989, 20(8):983-989.
13. Sacco R.L., Wolf P.A., Kannel W.B., et al. Survival and recurrence following stroke. The Framingham Study. Stroke 1982, 13(3):290-295.
14. Sacco R.L., Shi T., Zamanillo M.C., et al. Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: The Northern Manhattan Stroke Study. Neurology 1994, 44(4):626-634.
15. Brott T, Marks MP, Patel SC, et al: Acute Ischemic Stroke: New Concepts of Care 1998-1999: . http://www.strokecenter.org.
16. Arboix A., Font A., Garro C., et al. Recurrent lacunar infarction following a previous lacunar stroke: A clinical study of 122 patients. J Neurol Neurosurg Psychiatry 2007, 78(12):1392-1394.
17. Elkind M.S., Tai W., Coates K., et al. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006, 23;166(19):2073-2080.
18. Fuster V., Topol E.J., Nabel E.G. Atherothrombosis and coronary artery disease 2005, Lippincott Williams & Wilkins, Philadelphia. ed 2.
19. Wolf P.A., Kannel W.B., Sorlie P., et al. Asymptomatic carotid bruit and risk of stroke. The Framingham study. JAMA 1981, 245(14):1442-1445.
20. Sacco R.L., Benjamin E.J., Broderick J.P., et al. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. Stroke 1997, 28(7):1507-1517.
21. Howard G., Labarthe D.R., Hu J., et al. Regional differences in African Americans' high risk for stroke: The remarkable burden of stroke for Southern African Americans. Ann Epidemiol 2007, 17(9):689-696.
22. Sacco R.L., Boden-Albala B., Gan R., et al. Stroke incidence among white, black, and Hispanic residents of an urban community: The Northern Manhattan Stroke Study. Am J Epidemiol 1998, 147(3):259-268.
23. Kissela B., Schneider A., Kleindorfer D., et al. Stroke in a biracial population: The excess burden of stroke among blacks. Stroke 2004, 35(2):426-431.
24. Bravata D.M., Wells C.K., Gulanski B., et al. Racial disparities in stroke risk factors: The impact of socioeconomic status. Stroke 2005, 36(7):1507-1511.
25. Petty G.W., Brown R.D., Whisnant J.P., et al. Ischemic stroke subtypes: A population-based study of incidence and risk factors. Stroke 1999, 30(12):2513-2516.
26. MacMahon S., Rodgers A. The epidemiological association between blood pressure and stroke: Implications for primary and secondary prevention. Hypertens Res 1994, 17(suppl 1):S23-S32.
27. The Sixth Report of the Joint National Committee on Prevention: Detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997, 157(21):2413-2446.
28. Collins R., Peto R., MacMahon S., et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990, 335(8693):827-838.
29. Beckett N.S., Peters R., Fletcher A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008, 358(18):1887-1898.
30. Seshadri S., Wolf P.A., Beiser A., et al. Elevated midlife blood pressure increases stroke risk in elderly persons: The Framingham Study. Arch Intern Med 2001, 161(19):2343-2350.
31. Shahar E., Chambless L.E., Rosamond W.D., et al. Plasma lipid profile and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) study. Stroke 2003, 34(3):623-631.
32. Wolf P.A., D'Agostino R.B., Belanger A.J., et al. Are blood lipids risk factors for stroke?. Stroke 1991, 22(1):26.
33. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 1995, 346:1647-1653.
34. Iso H., Jacobs D.R., Wentworth D., et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989, 320(14):904-910.
35. Benfante R., Yano K., Hwang L.J., et al. Elevated serum cholesterol is a risk factor for both coronary heart disease and thromboembolic stroke in Hawaiian Japanese men. Implications of shared risk. Stroke 1994, 25(4):814-820.
36. Atkins D., Psaty B.M., Koepsell T.D., et al. Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann Intern Med 1993, 119(2):136-145.
37. Fine-Edelstein J.S., Wolf P.A., O'Leary D.H., et al. Precursors of extracranial carotid atherosclerosis in the Framingham Study. Neurology 1994, 44(6):1046-1050.
38. Wilson P.W.F., Hoeg J.M., Belanger A.J., et al. Cholesterol-years, blood pressure-years, pack-years and carotid stenosis. Circulation 1995, 92(8):1-519.
39. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group. Stroke 1996, 27(2):224-231.
40. Furberg C.D., Adams H.P., Applegate W.B., et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994, 90(4):1679-1687.
41. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344(8934):1383-1389.
42. Sacks F.M., Pfeffer M.A., Moye L.A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335(14):1001-1009.
43. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998, 339(19):1349-1357.
44. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003, 361(9364):1149-1158.
45. Yano K., Reed D.M., MacLean C.J. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 1989, 20(11):1460-1465.
46. Shimamoto T., Komachi Y., Inada H., et al. Trends for coronary heart disease and stroke and their risk factors in Japan. Circulation 1989, 79(3):503-515.
47. Burchfiel C.M., Curb J.D., Rodriguez B.L., et al. Glucose intolerance and 22-year stroke incidence. The Honolulu Heart Program. Stroke 1994, 25(5):951-957.
48. Barrett-Connor E., Khaw K.T. Diabetes mellitus: An independent risk factor for stroke?. Am J Epidemiol 1988, 128(1):116-123.
49. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241(19):2035-2038.
50. Najarian R.M., Sullivan L.M., Kannel W.B., et al. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med 2006, 166(1):106-111.
51. Walker S.P., Rimm E.B., Ascherio A., et al. Body size and fat distribution as predictors of stroke among US men. Am J Epidemiol 1996, 144(12):1143-1150.
52. Welin L., Svardsudd K., Wilhelmsen L., et al. Analysis of risk factors for stroke in a cohort of men born in 1913. N Engl J Med 1987, 317(9):521-526.
53. Seshadri S., Beiser A., Pikula A., et al. Parental occurrence of stroke and risk of stroke in their children: The Framingham Study. Circulation 2010, 121(11):1304-1312.
54. Wilhelmsen L., Svardsudd K., Korsan-Bengtsen K., et al. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984, 311(8):501-505.
55. Kannel W.B., Wolf P.A., Castelli W.P., et al. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987, 258(9):1183-1186.
56. Kannel W.B., D'Agostino R.B., Belanger A.J. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham Study. Am Heart J 1987, 113(4):1006-1010.
57. Folsom A.R., Qamhieh H.T., Flack J.M., et al. Plasma fibrinogen: Levels and correlates in young adults. The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Epidemiol 1993, 138(12):1023-1036.
58. Lee A.J., Lowe G.D., Woodward M., et al. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: The Scottish Heart Health Study. Br Heart J 1993, 69(4):338-342.
59. Rost N.S., Wolf P.A., Kase C.S., et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: The Framingham Study. Stroke 2001, 32(11):2575-2579.
60. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347(20):1557-1565.
61. Boushey C.J., Beresford S.A., Omenn G.S., et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995, 274(13):1049-1057.
62. Nygard O., Vollset S.E., Refsum H., et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995, 274(19):1526-1533.
63. Perry I.J., Refsum H., Morris R.W., et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995, 346(8987):1395-1398.
64. Stampfer M.J., Malinow M.R., Willett W.C., et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992, 268(7):877-881.
65. Verhoef P., Hennekens C.H., Malinow M.R., et al. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994, 25(10):1924-1930.
66. Malinow M.R., Nieto F.J., Szklo M., et al. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 1993, 87(4):1107-1113.
67. Selhub J., Jacques P.F., Bostom A.G., et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995, 332(5):286-291.
68. Selhub J., Jacques P.F., Wilson P.W., et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993, 270(22):2693-2698.
69. Toole J.F., Malinow M.R., Chambless L.E., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004, 291(5):565-575.
70. 12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 2010, 303(24):2486-2494.
71. Wolf P.A., Kannel W.B., McNamara P.M., et al. The role of impaired cardiac function in atherothrombotic brain infarction: The Framingham Study. Am J Public Health 1973, 63(1):52-58.
72. Loh E., Sutton M.S., Wun C.C., et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997, 336(4):251-257.
73. Smith P., Arnesen H., Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990, 323(3):147-152.
74. Murabito J.M., Evans J.C., Larson M.G., et al. The ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: The Framingham Study. Arch Intern Med 2003, 163(16):1939-1942.
75. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987, 147(9):1561-1564.
76. Chesebro J.H., Fuster V., Halperin J.L. Atrial fibrillation-risk marker for stroke. N Engl J Med 1990, 323(22):1556-1558.
77. Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991, 22(8):983-988.
78. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154:1449-1457.
79. Laupacis A., Albers G., Dalen J., et al. Antithrombotic therapy in atrial fibrillation. Chest 1998, 114(Suppl 5):579S-589S.
80. Sage J.I., Van Uitert R.L. Risk of recurrent stroke in patients with atrial fibrillation and non-valvular heart disease. Stroke 1983, 14(4):537-540.
81. Marini C., De Santis F., Sacco S., et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: Results from a population-based study. Stroke 2005, 36(6):1115-1119.
82. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA 1998, 279(16):1273-1277.
83. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med 1992, 116(1):1-5.
84. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001, 285(22):2864-2870.
85. van Walraven C., Hart R.G., Wells G.A., et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003, 163(8):936-943.
86. Hart R.G., Halperin J.L. Atrial fibrillation and thromboembolism: A decade of progress in stroke prevention. Ann Intern Med 1999, 131(9):688-695.
87. Wang T.J., Massaro J.M., Levy D., et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study. JAMA 2003, 290(8):1049-1056.
88. Fihn S.D., Callahan C.M., Martin D.C., et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996, 124(11):970-979.
89. Wang T.J., Larson M.G., Levy D., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003, 107(23):2920-2925.
90. Bikkina M., Levy D., Evans J.C., et al. Left ventricular mass and risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA 1994, 272(1):33-36.
91. Chabriat H., Vahedi K., Iba-Zizen M.T., et al. Clinical spectrum of CADASIL: A study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet 1995, 346:934-939.
92. Buring J.E., Hebert P., Romero J., et al. Migraine and subsequent risk of stroke in the Physicians' Health Study. Arch Neurol 1995, 52(2):129-134.
93. Carolei A., Marini C., De Matteis G. History of migraine and risk of cerebral ischaemia in young adults. The Italian National Research Council Study Group on Stroke in the Young. Lancet 1996, 347:1503-1506.
94. Wolf P.A., D'Agostino R.B., Kannel W.B., et al. Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA 1988, 259(7):1025-1029.
95. Colditz G.A., Bonita R., Stampfer M.J., et al. Cigarette smoking and risk of stroke in middle-aged women. N Engl J Med 1988, 318(15):937-941.
96. Abbott R.D., Yin Y., Reed D.M., et al. Risk of stroke in male cigarette smokers. N Engl J Med 1986, 315(12):717-720.
97. Further analyses of mortality in oral contraceptive users: Royal College of General Practitioners' Oral Contraception Study. Lancet 1981, 317:541-546.
98. Sacco R.L., Wolf P.A., Bharucha N.E., et al. Subarachnoid and intracerebral hemorrhage: natural history, prognosis, and precursive factors in the Framingham Study. Neurology 1984, 34(7):847-854.
99. Bonita R. Cigarette smoking, hypertension and the risk of subarachnoid hemorrhage: A population-based case-control study. Stroke 1986, 17(5):831-835.
100. Fogelholm R., Murros K. Cigarette smoking and subarachnoid haemorrhage: A population-based case-control study. J Neurol Neurosurg Psychiatry 1987, 50(1):78-80.
101. Shinton R., Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989, 298(6676):789-794.
102. Stadel B.V. Oral contraceptives and cardiovascular disease (second of two parts). N Engl J Med 1981, 305(12):672-677.
103. Adams H.P., Butler M.J., Biller J., et al. Nonhemorrhagic cerebral infarction in young adults. Arch Neurol 1986, 43(8):793-796.
104. Stampfer M.J., Willett W.C., Colditz G.A., et al. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1988, 319:1313-1317.
105. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996, 348:498-505. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study.
106. Petitti D.B., Sidney S., Bernstein A., et al. Stroke in users of low-dose oral contraceptives. N Engl J Med 1996, 335(1):8-15.
107. Gillum L.A., Mamidipudi S.K., Johnston S.C. Ischemic stroke risk with oral contraceptives: A meta-analysis. JAMA 2000, 284(1):72-78.
108. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1996, 348:505-510.
109. Viscoli C.M., Brass L.M., Kernan W.N., et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001, 345(17):1243-1249.
110. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3):321-333.
111. Stampfer M.J., Colditz G.A., Willett W.C., et al. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med 1988, 319(5):267-273.
112. Djousse L., Ellison R.C., Beiser A., et al. Alcohol consumption and risk of ischemic stroke: The Framingham Study. Stroke 2002, 33(4):907-912.
113. Donahue R.P., Abbott R.D., Reed D.M., et al. Alcohol and hemorrhagic stroke. The Honolulu Heart Program. JAMA 1986, 255(17):2311-2314.
114. Camargo C.A. Moderate alcohol consumption and stroke. The epidemiologic evidence. Stroke 1989, 20:1611-1626.
115. Hillbom M., Kaste M., Rasi V. Can ethanol intoxication affect hemocoagulation to increase the risk of brain infarction in young adults?. Neurology 1983, 33(3):381-384.
116. Ettinger P.O., Wu C.F., De La Cruz C., et al. Arrhythmias and the "Holiday Heart": alcohol-associated cardiac rhythm disorders. Am Heart J 1978, 95(5):555-562.
117. Taylor J.R., Combs-Orme T. Alcohol and strokes in young adults. Am J Psychiatry 1985, 142(1):116-118.
118. Gorelick P.B. The status of alcohol as a risk factor for stroke. Stroke 1989, 20(12):1607-1610.
119. Manson J.E., Stampfer M.J., Willett W.C., et al. Physical activity and incidence of coronary heart disease and stroke in women [abstract]. Circulation 1995, 91:927.
120. Abbott R.D., Rodriguez B.L., Burchfiel C.M., et al. Physical activity in older middle-aged men and reduced risk of stroke: The Honolulu Heart Program. Am J Epidemiol 1994, 139(9):881-893.
121. Wannamethee G., Shaper A.G. Physical activity and stroke in British middle aged men. BMJ 1992, 304:597-601.
122. Kiely D.K., Wolf P.A., Cupples L.A., et al. Physical activity and stroke risk: The Framingham Study. Am J Epidemiol 1994, 140(7):608-620.
123. Gillum R.F., Mussolino M.E., Ingram D.D. Physical activity and stroke incidence in women and men. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol 1996, 143(9):860-869.
124. Lee I.M., Hennekens C.H., Berger K., et al. Exercise and risk of stroke in male physicians. Stroke 1999, 30(1):1-6.
125. Liu S., Manson J.E., Stampfer M.J., et al. Whole grain consumption and risk of ischemic stroke in women: A prospective study. JAMA 2000, 284(12):1534-1540.
126. Joshipura K.J., Ascherio A., Manson J.E., et al. Fruit and vegetable intake in relation to risk of ischemic stroke. JAMA 1999, 282:1233-1239.
127. Iso H., Rexrode K.M., Stampfer M.J., et al. Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA 2001, 285(3):304-312.
128. Yokoyama T., Date C., Kokubo Y., et al. Serum vitamin C concentration was inversely associated with subsequent 20-year incidence of stroke in a Japanese rural community: the Shibata Study. Stroke 2000, 31:2287-2294.
129. Ascherio A., Rimm E.B., Hernan M.A., et al. Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States. Ann Intern Med 1999 Jun 15, 130(12):963-970.
130. Gillum R.F., Mussolino M.E., Madans J.H. The relationship between fish consumption and stroke incidence. The NHANES I Epidemiologic Follow-up Study (National Health and Nutrition Examination Survey). Arch Intern Med 1996, 156(5):537-542.
131. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847.
132. Leaverton P.E., Sorlie P.D., Kleinman J.C., et al. Representativeness of the Framingham risk model for coronary heart disease mortality: A comparison with a national cohort study. J Chronic Dis 1987, 40(8):775-784.
133. Brand R.J., Rosenman R.H., Sholtz R.I., et al. Multivariate prediction of coronary heart disease in the Western Collaborative Group Study compared to the findings of the Framingham study. Circulation 1976, 53(2):348-355.
134. Kannel W.B., Gordon T. The Framingham Study; an epidemiological investigation of cardiovascular disease 1968, National Heart Institute (U.S.), U.S. Dept. of Health, Education, and Welfare, National Institutes of Health; US Government Printing Office, Washington, DC, Bethesda, Md.
135. Wolf P.A., D'Agostino R.B., Belanger A.J., et al. Probability of stroke: A risk profile from the Framingham Study. Stroke 1991, 22(3):312-318.